MAGEA9 and primary cutaneous T-cell non-Hodgkin lymphoma: MAGEA9 is frequently overexpressed in bladder cancer, cutaneous T-cell lymphomas, oesophageal adenocarcinomas, as well as in renal cell carcinoma [51,52,53,54].